Episode # 59 • 12 May 2026
Evolving Treatment Paradigms in Hepatocellular Carcinoma: What's on the Horizon?
As the HCC landscape evolves, which new targets and strategies are set to shape clinical practice? In this final episode of the BackTable 2026 HCC Creator Weekend™, Drs. Lingling Du, A. Craig Lockhart, and Jon Mizrahi focus on the future of HCC care beyond established PD-1/CTLA-4 regimens.
Timestamps
00:00 - Introduction
01:34 - Beyond PD-1 and CTLA-4: Anti-TIGIT plus Atezolizumab
03:24 - Combination Strategies: Immunotherapy plus Radioembolization
09:14 - SBRT in Oligometastatic Disease
10:55 - Neoadjuvant Immunotherapy in HCC
12:07 - Targeted Therapies: ctDNA, CAR T-cells & GPC3
15:18 - Liver Transplant & Immunotherapy
23:07 - Future Directions and Closing Thoughts
You may also like
More about this episode
The clinicians discuss promising results from emerging immune checkpoint targets like anti-TIGIT and note ongoing interest in other targets like TIM-3. They emphasize combining systemic immunotherapy with liver-directed therapies like Y90 across heterogeneous patient groups and discuss potential neoadjuvant approaches for resectable cases, despite limited benefit seen in adjuvant studies. Additionally, they outline early-phase cellular and targeted strategies, such as GPC3-directed bispecifics and CAR T-cell therapies, noting tolerance challenges tied to liver function and the risks of using immunotherapy after liver transplant.
The Materials available on BackTable are provided for informational and educational purposes only and are not a substitute for the independent professional judgment of a qualified healthcare professional in diagnosing or treating patients. Any opinions, statements, or views expressed are those of the individual contributors and do not necessarily reflect those of the publisher, platform, or any affiliated organization.